Amantadine Might be Used as a Drug for SARS-Cov-2 Treatment?
Coronaviruses, cilt.2, sa.1, ss.6-7, 2021 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 2 Sayı: 1
- Basım Tarihi: 2021
- Doi Numarası: 10.2174/2666796701999200713192912
- Dergi Adı: Coronaviruses
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.6-7
- Anahtar Kelimeler: Amantadine, COVID-19, drug repositioning, neurology, pharmacology, SARS-CoV-2
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Maltepe Üniversitesi Adresli: Evet
Özet
Coronavirus Disease 2019 (COVID-19) infection, the pandemics, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has no known effective radical pharmacotherapy and just supportive approach at present. Amantadine is a drug used in Parkinson’s disease and other parkin-sonisms; and is known to increase indirectly dopamine by antagonistic effects at the N-methyl-D-aspartate (NMDA) receptor by increasing the release and blocking the reuptake of dopamine. Initially, amantadine was approved as an antiviral drug. We hypothesize that if amantadine is considered its anti-viral, immunological and neurostimulant effects might be useful in the supportive treatment of SARS-CoV-2 cases, especially those who developed acute respiratory failure with decreased vigilance and are being monitored in the intensive care unit. Further phase III clinical trials are needed.